Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Clemente-Suárez Vicente Javier, Olivares Rodrigo, Yáñez-Sepúlveda Rodrigo, Guzmán-Muñóz Eduardo, Rodríguez Alexandra Martín
Аннотация
BACKGROUND: The prognostic relevance of ultra-rare TP53 and KRAS variants in advanced solid tumours treated with immune-checkpoint inhibitors (ICI) is unclear.
METHODS: We performed a retrospective cohort study using the Memorial Sloan Kettering Cancer Center MSK-IMPACT clinical-genomic dataset (cBioPortal study ID: tmb_mskcc_2018). TP53 and KRAS alterations were stratified by rarity (ultra-rare vs common) and analysed for overall survival (OS). Kaplan-Meier analyses and multivariable Cox proportional hazards models were fitted, adjusting for tumour type, tumour mutational burden (TMB), tumour purity, histology, age and sex.
RESULTS: In the overall cohort, 51.4% of tumours harboured TP53 or KRAS mutations. Ultra-rare variants were independently associated with worse OS (HR 1.34, 95% CI 1.14-1.56; p < 0.001), with a median OS of 14.0 months versus 22.0 months in common/wild-type patients. Tumour-specific analyses suggested heterogeneity: non-small-cell lung cancer showed shorter OS for ultra-rare variants (approximately 10-13 months vs 17 months for wild type), whereas melanoma showed improved outcomes (HR 0.59, 95% CI 0.44-0.78; p < 0.001).
CONCLUSION: Ultra-rare TP53 and KRAS variants provide prognostic information in ICI-treated advanced solid tumours, but the direction and magnitude of effect vary by tumour type. These findings support tumour-specific interpretation and motivate mechanistic and therapeutic studies in this underserved molecular subgroup.
METHODS: We performed a retrospective cohort study using the Memorial Sloan Kettering Cancer Center MSK-IMPACT clinical-genomic dataset (cBioPortal study ID: tmb_mskcc_2018). TP53 and KRAS alterations were stratified by rarity (ultra-rare vs common) and analysed for overall survival (OS). Kaplan-Meier analyses and multivariable Cox proportional hazards models were fitted, adjusting for tumour type, tumour mutational burden (TMB), tumour purity, histology, age and sex.
RESULTS: In the overall cohort, 51.4% of tumours harboured TP53 or KRAS mutations. Ultra-rare variants were independently associated with worse OS (HR 1.34, 95% CI 1.14-1.56; p < 0.001), with a median OS of 14.0 months versus 22.0 months in common/wild-type patients. Tumour-specific analyses suggested heterogeneity: non-small-cell lung cancer showed shorter OS for ultra-rare variants (approximately 10-13 months vs 17 months for wild type), whereas melanoma showed improved outcomes (HR 0.59, 95% CI 0.44-0.78; p < 0.001).
CONCLUSION: Ultra-rare TP53 and KRAS variants provide prognostic information in ICI-treated advanced solid tumours, but the direction and magnitude of effect vary by tumour type. These findings support tumour-specific interpretation and motivate mechanistic and therapeutic studies in this underserved molecular subgroup.